Works matching IS 01791958 AND DT 2024 AND VI 39 AND IP 1

Results: 191
    1
    2
    3
    4
    5
    6
    7

    Association between social background and implementation of postoperative adjuvant chemotherapy for older patients undergoing curative resection of colorectal cancers, sub-analysis of the HiSCO-04 study.

    Published in:
    International Journal of Colorectal Disease, 2024, v. 39, n. 1, p. 1, doi. 10.1007/s00384-023-04583-7
    By:
    • Bekki, Tomoaki;
    • Shimomura, Manabu;
    • Saito, Yasufumi;
    • Nakahara, Masahiro;
    • Adachi, Tomohiro;
    • Ikeda, Satoshi;
    • Shimizu, Yosuke;
    • Kochi, Masatoshi;
    • Ishizaki, Yasuyo;
    • Yoshimitsu, Masanori;
    • Takakura, Yuji;
    • Shimizu, Wataru;
    • Sumitani, Daisuke;
    • Kodama, Shinya;
    • Fujimori, Masahiko;
    • Oheda, Mamoru;
    • Kobayashi, Hironori;
    • Akabane, Shintaro;
    • Yano, Takuya;
    • Ohdan, Hideki
    Publication type:
    Article
    8
    9
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19

    Anastomotic leakage after resection for rectal cancer and recurrence-free survival in relation to postoperative C-reactive protein levels.

    Published in:
    International Journal of Colorectal Disease, 2024, v. 39, n. 1, p. 1, doi. 10.1007/s00384-024-04766-w
    By:
    • Gerdin, Anders;
    • Park, Jennifer;
    • Häggström, Jenny;
    • Segelman, Josefin;
    • Matthiessen, Peter;
    • Lydrup, Marie-Louise;
    • Rutegård, Martin;
    • on behalf of the RectoLeak Study Group;
    • Sjöström, Östersund Olle;
    • Staffan, Falun Maria;
    • Jangmalm, Växjö Staffan;
    • Royson, Växjö Hanna;
    • Tsimogiannis, Uppsala Konstantinos;
    • Anderin, Ersta Kajsa;
    • Nygren, Ersta Jonas;
    • Hurtig, Luleå Jennie;
    • Golshani, Gävle Parisa
    Publication type:
    Article
    20
    21

    Combining moderate dosage of Bevacizumab with TAS-102 provides longer progression-free time in refractory metastatic colorectal Cancer.

    Published in:
    International Journal of Colorectal Disease, 2024, v. 39, n. 1, p. 1, doi. 10.1007/s00384-024-04767-9
    By:
    • Tseng, Kuan-Yu;
    • Yang, Mu-Ying;
    • Chen, Wei-Shone;
    • Jiang, Jeng-Kai;
    • Wang, Huann-Sheng;
    • Chang, Shih-Ching;
    • Lan, Yuan-Tzu;
    • Lin, Chun-Chi;
    • Lin, Hung-Hsin;
    • Huang, Sheng-Chieh;
    • Cheng, Hou-Hsuan;
    • Yang, Yi-Wen;
    • Lin, Yu-Zu;
    • Chang, Che-Yuan;
    • Teng, Hao-Wei
    Publication type:
    Article
    22
    23
    24
    25
    26
    27
    28
    29
    30
    31
    32
    33
    34
    35
    36
    37
    38
    39
    40
    41
    42

    Impact on survival benefits of asymptomatic primary tumor resection after bevacizumab plus FOLFIRI as first-line therapy for patients with metastatic colorectal cancer with synchronous unresectable metastasis.

    Published in:
    International Journal of Colorectal Disease, 2024, v. 39, n. 1, p. 1, doi. 10.1007/s00384-024-04745-1
    By:
    • Chen, Yen-Cheng;
    • Chang, Tsung-Kun;
    • Su, Wei-Chih;
    • Yeh, Yung-Sung;
    • Chen, Po-Jung;
    • Huang, Peng-Jen;
    • Yang, Po-Hsiang;
    • Tsai, Hsiang-Lin;
    • Wang, Jaw-Yuan;
    • Huang, Ching-Wen
    Publication type:
    Article
    43
    44
    45
    46
    47
    48
    49
    50